Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
November 2012, Vol 3, No 8
November 2012, Vol 3, No 8
The Missing Perspective in Personalized Cancer Care
By
Caroline Helwick
Personalized Medicine
November 2012, Vol 3, No 8
Vienna, Austria—The identification of genetic mutations and tumor biomarkers to select the right drug for the right patient are not enough to satisfy the need for personalized cancer care, according to Kathy Redmond, MSc, RN, Editor of Cancer World magazine, a publication of the European School of Oncology and former president of the European Oncology Nursing Society, who addressed the topic of personalized medicine at the 2012 European Society for Medical Oncology Congress.
Read Article
A New Personalized Prescription Decision-Making System
By
Rosemary Frei, MSc
Personalized Medicine
November 2012, Vol 3, No 8
Phoenix, AZ—Using the paradigm of individualizing drug therapy based on a patient’s genetics, a group of oncologists and genomic experts have designed a genomic prescribing system that they hope will significantly reduce the staggeringly high rate of adverse drug reactions associated with prescription drugs in the United States.
Read Article
How Will We Pay for Cancer Treatment?
By
Ted Okon, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
With the fanfare of a New York Times Op-Ed piece by Peter B. Bach, MD, and colleagues, the announcement was made that Memorial Sloan-Kettering Cancer Center (MSKCC) would exclude the new colorectal cancer drug ziv-aflibercept (Zaltrap) from its formulary.
Read Article
Payers’ Support of Clinical Decisions Allows Providers to Choose Most Effective, Cost-Saving Therapies
By
Ira Klein, MD, MBA, FACP
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
The cost of cancer care is staggering. Global sales of cancer drugs alone are forecast to grow at a rate of 12% to 15% annually, reaching $75 billion to $80 billion by the end of this year, according to IMS Health.
Read Article
Cumulative Financial Impact of Skeletal-Related Events on Patients with Breast Cancer Is Significant
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
November 2012, Vol 3, No 8
San Francisco, CA—In patients with breast cancer with bone metastases, skeletal-related events (SREs) are associated with high treatment costs. For example, the cumulative cost of treating 1 spinal cord compression exceeds $100,000, according to a new cost analysis presented at the 2012 Breast Cancer Symposium.
Read Article
A Rational Step in Holding Down Costs in Cancer Care
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
November 2012, Vol 3, No 8
The cost of cancer care matters; in fact, it matters so much that Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City has decided not to include in its formulary the newly approved drug ziv-aflibercept (Zaltrap), which was recently approved for use in patients with progressive metastatic colorectal cancer.
Read Article
Proton Beam Therapy: Similar Toxicity to Standard Radiation, at Much Higher Cost
By
Phoebe Starr
ASTRO Annual Meeting
November 2012, Vol 3, No 8
A study presented at the 2012 American Society for Radiation Oncology annual meeting found few differences in toxicity between the 2 techniques, but demonstrated that PBRT was associated with a 57% increase in median cost per patient.
Read Article
Statin Therapy Improves Survival in Patients with Cancer
In the Literature
November 2012, Vol 3, No 8
Researchers in Denmark set out to investigate whether statin therapy can help to reduce cancer-related mortality by limiting cancer-cell proliferation in patients who have used statins before they were diagnosed with cancer (Nielsen SF, et al. N Engl J Med. 2012;367:1792-1802).
Read Article
Synribo Approved for CML Abraxane for NSCLC
FDA Approvals, News & Updates
November 2012, Vol 3, No 8
The US Food and Drug Administration (FDA) approved omacetaxine mepesuccinate (Synribo; Teva Pharmaceutical) to treat adults with chronic myelogenous leukemia (CML), a hematologic disease. An estimated 5430 Americans will be diagnosed with CML in 2012, according to the National Institutes of Health.
Read Article
Stereotactic Body Radiation Therapy Cost-Saving, Convenient for Patients with Prostate Cancer
By
Phoebe Starr
ASTRO Annual Meeting
November 2012, Vol 3, No 8
Boston, MA—In the United States right now, intensity modulated radiation therapy (IMRT) has largely replaced 3-dimensional conformal radiation therapy as the technique of choice for most patients with organ-confined prostate cancer that is being treated with radiation as the primary therapy.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma